Balyasny Asset Management
NBIX icon

Balyasny Asset Management’s Neurocrine Biosciences NBIX Stock Holding History

Balyasny Asset Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-50,000
Closed -$5.63M – 2756
2023
Q3 		$5.63M Hold
50,000
– – 0.01% 1064
2023
Q2 		$4.71M Buy
+50,000
New +$4.89M 0.01% 1085
2019
Q4 		– Sell
-240,000
Closed -$21.6M – 1373
2019
Q3 		$21.6M Buy
+240,000
New +$22.4M 0.15% 225
2018
Q3 		– Sell
-110,400
Closed -$10.8M – 1922
2018
Q2 		$10.8M Buy
+110,400
New +$9.88M 0.05% 467

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Balyasny Asset Management's NBIX Position: Q1 2026 in Review

Balyasny Asset Management sold out of Neurocrine Biosciences (NBIX) in Q1 2026, closing a stake of 141,101 shares — an estimated $20M sold.

Balyasny Asset Management first reported a position in NBIX in Q2 2015 and held it in 23 quarters. The position peaked at $73.1M in Q2 2023. 696 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

  • Balyasny Asset Management reported no remaining Neurocrine Biosciences position as of Q1 2026 after selling out during the quarter.
  • Balyasny Asset Management sold 141,101 Neurocrine Biosciences shares in Q1 2026, an estimated $20M.
  • Balyasny Asset Management first reported a position in Neurocrine Biosciences in Q2 2015 and held it in 23 quarters.
  • Balyasny Asset Management's Neurocrine Biosciences position peaked at $73.1M in Q2 2023.
  • 696 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.